Cytokine fusion protein treatment.

Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.
AuthorsDavid Schrama, Per thor Straten, Eva-Bettina Bröcker, Ralph A Reisfeld, Jürgen C Becker
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer (Recent Results Cancer Res) Vol. 160 Pg. 185-94 ( 2002) ISSN: 0080-0015 [Print] Germany
PMID12079213 (Publication Type: Journal Article)
Chemical References
  • Cytokines
  • Lymphotoxin-alpha
  • Recombinant Fusion Proteins
  • Animals
  • Clone Cells
  • Cytokines (therapeutic use)
  • Lymphotoxin-alpha (therapeutic use)
  • Melanoma, Experimental (therapy)
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Fusion Proteins (therapeutic use)
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes (immunology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: